Tirzepatide
Metabolic
ABOUT
Tirzepatide is a dual GIP and GLP-1 receptor agonist. U.S. labels differ by product and indication; the cited Zepbound label includes chronic weight-management and obstructive-sleep-apnoea indications for specified adults.
EVIDENCE OVERVIEW
Supported by controlled human trials
WHAT THIS MEANS
Established. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Tirzepatide is a single 39-amino-acid peptide that agonises both the GIP and GLP-1 receptors - a dual incretin agonist rather than a GLP-1 agonist with an additive. A C20 fatty-diacid moiety confers albumin binding and the once-weekly profile. The GIP component is the pharmacological difference from semaglutide, and the clinical consequence of that difference is still being characterised.
PHARMACOKINETICS
Half-life approximately five days, supporting once-weekly dosing, with steady state reached after about four weeks. Eliminated by proteolysis into amino acids with metabolism of the fatty-diacid side chain.
REVIEW
PUBLISHED PAIR RECORDS
with Semaglutide
Prescription GLP-1 coadministration is not recommendedTirzepatide product labelling states that coadministration with another GLP-1 receptor agonist is not recommended. This is prescription-product guidance, not a conclusion about every preparation or an individual treatment plan; a prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Retatrutide
Overlapping incretin-receptor activityTirzepatide and investigational retatrutide both act at GIP and GLP-1 receptors. No curated direct combination study was identified. Tirzepatide labelling advises against coadministration with GLP-1 receptor agonists, so this combination warrants clinician or pharmacist review rather than self-directed stacking.
Reviewed 19 Aug 2026with Survodutide
Overlapping incretin-pathway activityTirzepatide and Survodutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Mazdutide
Overlapping incretin-pathway activityTirzepatide and Mazdutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Cagrilintide
Overlapping incretin-pathway activityTirzepatide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Native GIP
Overlapping incretin-pathway activityTirzepatide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Opposing effects on glucose regulationMK-677 raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Tirzepatide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Opposing effects on glucose regulationTesamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Tirzepatide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Opposing effects on glucose regulationCJC-1295 with DAC raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Tirzepatide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Opposing effects on glucose regulationSermorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Tirzepatide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Ipamorelin
Opposing effects on glucose regulationIpamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Tirzepatide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with PT-141
Additive delay of gastric emptyingBremelanotide (PT-141) labelling states that it slows gastric emptying and may reduce the rate and extent of absorption of concomitantly administered oral medicines - patients are advised to avoid it alongside oral drugs that depend on threshold concentrations, and to avoid oral naltrexone products entirely because exposure is significantly decreased. Approved GLP-1 labelling carries the same gastric-emptying caution. Scheduling Tirzepatide alongside PT-141 therefore stacks two agents that independently delay gastric emptying, which matters most for any oral medicine taken in the same window. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Liraglutide
Overlapping incretin-pathway activityLiraglutide and Tirzepatide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are approved prescription products carrying that labelling. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Exenatide
Overlapping incretin-pathway activityExenatide and Tirzepatide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are approved prescription products carrying that labelling. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Dulaglutide
Overlapping incretin-pathway activityDulaglutide and Tirzepatide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are approved prescription products carrying that labelling. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Pramlintide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Tirzepatide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Teduglutide
Opposing effects on intestinal absorptionTeduglutide is a GLP-2 analogue that increases villus height and crypt depth, enlarging absorptive surface area; its labelling records a potential for increased absorption of concomitant oral medicines and advises monitoring where a drug is titrated or has a narrow therapeutic index, since the oral drug may need its dose reduced. Tirzepatide works in the opposite direction on the same variable - incretin-pathway labelling and pharmacology describe delayed gastric emptying, which slows the rate at which an oral medicine reaches the small intestine. One agent is enlarging the absorptive surface while the other is changing the timing of delivery to it, so the net effect on any co-administered oral medicine is not predictable from either alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Larazotide acetate
Delayed gastric emptying may alter delivery of an enteric-coated oralTirzepatide labelling states that it delays gastric emptying and may affect the rate and extent of absorption of concomitantly administered oral medicines. Larazotide acetate is given as an enteric-coated oral capsule designed to release in the small intestine, acts locally on tight junctions there, and is minimally absorbed systemically - so what matters for it is where and when the capsule arrives, not a plasma concentration. Changing gastric emptying changes that delivery. Larazotide's own confirmatory phase 3 trial was stopped at interim analysis for futility, so there is no established effect size for it to lose in the first place; the interaction concern is about delivery, not about diminishing a proven benefit. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains Ipamorelin, and the catalogue holds a curated pair record between that component and Tirzepatide: Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and Tirzepatide: CJC-1295 with DAC (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and Tirzepatide: Sermorelin (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Kyinsu
Inherited from a component of this blendKyinsu contains Semaglutide, and the catalogue holds a curated pair record between that component and Tirzepatide: Semaglutide (prescription glp-1 coadministration is not recommended). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CagriSema
Inherited from a component of this blendCagriSema contains Semaglutide and Cagrilintide, and the catalogue holds a curated pair record between those components and Tirzepatide: Semaglutide (prescription glp-1 coadministration is not recommended); Cagrilintide (overlapping incretin-pathway activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), and subsequently for moderate-to-severe obstructive sleep apnoea in adults with obesity. SURMOUNT-1 reported mean weight reduction of about 20.9% at the highest dose over 72 weeks, the largest for an approved agent at the time. SURPASS trials established glycaemic superiority over semaglutide 1 mg in type 2 diabetes.
REPORTED EFFECTS
Boxed warning for thyroid C-cell tumours from rodent studies; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Gastrointestinal adverse reactions predominate - nausea, diarrhoea, vomiting, constipation, dyspepsia - and are dose-related. Labelled warnings cover pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity, diabetic retinopathy complications and hypoglycaemia with insulin secretagogues. The label states that coadministration with another GLP-1 receptor agonist is not recommended.
RESEARCH LIMITATIONS
This is a label summary, not a recommendation. Product-specific contraindications, warnings, concomitant-medicine considerations, and country approvals must be checked against the current official label and with a qualified clinician.
CURATED SOURCES · 2